Jun 04, 2020
Espero BioPharma, Inc. Expands Collaboration Effort for Tecarfarin
May 14, 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
May 11, 2020
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020
CryoLife Initiates Enrollment in PROACT Xa Clinical Trial
May 05, 2020
Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
Apr 23, 2020
Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020
Apr 16, 2020
Aging Populations Will Increase Demand in the $35,802 Million Antithrombotic Drugs Market, Reports TBRC
Apr 07, 2020
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
Mar 25, 2020
Apixaban (CAS 503612-47-3) Market Research Report 2020 - ResearchAndMarkets.com
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 05, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Feb 24, 2020
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Feb 03, 2020
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer
Dec 23, 2019
FDA approves first generics of Eliquis
Dec 23, 2019
Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020
Dec 23, 2019
CryoLife Receives FDA Authorization to Commence PROACT Xa Clinical Trial
Nov 06, 2019
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
Oct 28, 2019
Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding
Aug 22, 2019
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aug 07, 2019
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update